# Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

> **NCT00031733** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 60 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** recombinant interleukin-12
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** tyrosinase peptide
- **DRUG:** alum adjuvant
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00031733
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2004-12
- **Final completion:** 2007-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00031733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00031733, "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00031733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*